FindTrial
Sign In

Artemisinin resistance in Plasmodium vivax

Estimation of prevalence of mutation in Artemisinin drug resistance associated with Pvk12 gene in Plasmodium vivax malaria parasite isolate in a tertiary care centre

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/03/018059
Enrollment
100
Registered
2019-03-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B519- Plasmodium vivax malaria without complication

Interventions

Intervention1: NIL: NIL

Sponsors

Research Society
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Females and males of age 18 to 70 year with clinically suspected malaria on treatment with antimalarials and/or uncomplicated symptomatic malaria (proven) as indicated by the presence of blood smears positive for Plasmodium vivax malaria Willing to provide written informed consent

Exclusion criteria

Exclusion criteria: Patients with Plasmodium falciparum and mixed infection

Design outcomes

Primary

MeasureTime frame
To determine the prevalence of mutation in the artemisinin drug resistance associated with genes in P.vivax malaria isolates by nested- PCRTimepoint: September 2019—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactPrajakta Gandhe

Seth GSMC and KEM Hospital Parel Mumbai

urmilathatte@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026